Oracle's $300 billion deal with OpenAI established it as a major player in AI cloud computing alongside Amazon, Google and ...

Oracle Corporation is rated a Buy due to robust execution, margin inflection, and high potential cloud growth opportunity.

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

Oracle (ORCL) earnings show 20% revenue growth with stable margins, strong cloud/AI backlog and upside valuation potential.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the AI stocks that will go to the moon. On February 18, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) came under pressure after regulatory ...

The additional spend covers redundancy packages and other exit costs as increasingly powerful AI models allow the company to cut software jobs.

Oracle's OCI revenue is growing 66% YOY, outpacing AWS and Azure. Oracle is selling profitable business units and accumulating tens of billions in debt to fund the data center expansion needed to ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Oracle Corporation (NYSE:ORCL) Q3 2026 Earnings Call Transcript March 10, 2026 Oracle Corporation beats earnings expectations. Reported EPS is $1.79, expectations were $1.7. Operator: Hello, and thank ...

Oracle loses executives health division as several senior leaders depart its health records unit following the Cerner acquisition.

The Larry Ellison–led software giant is remaking its cloud infrastructure to rival Amazon and Microsoft.

Oracle's Mike Sicilia is the latest software CEO to wade in to the debate on whether artificial intelligence tools that heavily automate human tasks will mean the demise of his industry. His verdict ...